News | April 11, 2014

Boston Scientific Begins Expansion of S-ICD System in Asia

First implant of the S-ICD system performed in Hong Kong


April 11, 2014 — Boston Scientific Corp. has expanded the launch of its S-ICD (subcutaneous implantable cardioverter-defibrillator) system into parts of Asia. The first implant of the S-ICD in Asia was performed in Hong Kong by Hung-Fat Tse, professor of cardiovascular medicine, University of Hong Kong, and department of medicine, Queen Mary Hospital in Pokfulam, Hong Kong, under the proctorship of Dr. Martin Stiles, director of electrophysiology, Waikato Hospital in Hamilton, New Zealand. 

Recent estimates show that almost 2 million people in the Asia Pacific region are at risk of sudden cardiac arrest (SCA) but are currently unprotected. The S-ICD system can provide protection for at-risk patients, leaving the heart and blood vessels untouched, and offering patients a compelling alternative to transvenous implantable cardioverter defibrillators (TV-ICDs), which require leads to be placed in the heart. Implantation of the S-ICD system uses anatomical landmarks without the need for fluoroscopy.

"The S-ICD system is a revolutionary and unique option for patients at risk of SCA," said Tse. "I envision the S-ICD system to be the first-choice solution for eligible patients because it provides a less invasive therapy with performance as good as TV-ICDs." 

This defibrillation therapy has been commercially available in Europe since 2009 and was approved in the United States in late 2012. Boston Scientific continues to expand the availability of this unique therapy for patients and physicians around the world. 

"Most of the world's population resides in Asia, which includes a high portion of unprotected patients at risk of SCA. The S-ICD system highlights Boston Scientific's commitment to bring meaningful innovation to patients and physicians in this critically important region," said Supratim Bose, executive vice president and president for Asia, Middle East and Africa, Boston Scientific.

The S-ICD does not have regulatory approval in China, Japan or South Korea and is not available for sale in those countries.

For more information: www.bostonscientific.com

 


Related Content

News | Implantable Cardioverter Defibrillator (ICD)

Sept. 2, 2024 – Medtronic recently shared long-term results from the global Extravascular Implantable Cardioverter ...

Home September 05, 2024
Home
News | Implantable Cardioverter Defibrillator (ICD)

February 12, 2024 — BIOTRONIK, a leader in implantable medical device technology, announced today they will solely ...

Home February 12, 2024
Home
News | Implantable Cardioverter Defibrillator (ICD)

October 23, 2023 — Medtronic plc, a global leader in healthcare technology, has received U.S. Food and Drug ...

Home October 23, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Is the routine implantation of an implantable cardioverter defibrillator (ICD) in myocardial ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

July 18, 2023 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall on the Medtronic ICDs and CRT-Ds ...

Home July 18, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

March 7, 2023 — Ninety-five percent of athletes with a diagnosed and treated genetic heart disease experienced no ...

Home March 07, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

February 17, 2023 — Medtronic plc has received CE (Conformité Européenne) Mark for the Aurora EV-ICD MRI SureScan ...

Home February 17, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 29, 2022 — Medtronic plc announced that its investigational EV ICD System – a first-of-its-kind defibrillator ...

Home August 29, 2022
Home
Subscribe Now